Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

NET 42Gastrointestinal 42Endocrine 42Sarcoma 4CNS 4Thoracic 3Other solid neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Genitourinary 1Breast 1

Conditions

Brain Neoplasms 1902Glioblastoma 1795Glioma 1127Central Nervous System Neoplasms 599Astrocytoma 593Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 363Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 226Recurrence 199Sarcoma 183Neoplasm Metastasis 183Melanoma 181Meningioma 177Ependymoma 175Lung Neoplasms 157Lymphoma 133Osteosarcoma 126Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 100Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1PM 01183 1Lutetium-177 1Lutetium 1Irinotecan 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Gastro-enteropancreatic neuroendocrine tumor × CNS × Clear all
NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Perspective Therapeutics

Phase 1/2 Recruiting
300 enrolled
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06441331 2026-05-01

KinLET

ITM Solucin GmbH

Phase 1 Recruiting
20 enrolled
CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡